Cargando…
Dissected subgroups predict the risk of recurrence of stage II colorectal cancer and select rational treatment
BACKGROUND: Stage II colorectal cancer(CRC) patients after surgery alone have a five-year survival rate of ~60-80%; the incremental benefit of adjuvant chemotherapy is <5%. Predicting risk of recurrence and selecting effective personalized adjuvant drugs for stage II CRC using formalin-fixed, par...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076777/ https://www.ncbi.nlm.nih.gov/pubmed/37033948 http://dx.doi.org/10.3389/fimmu.2023.1103741 |